Ikris Pharma
About Us Named Patient Program
Contact Us
Agilus

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

You can also access detailed information by clicking Login in the website header.

Agilus

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Agilus
Generic Name (API): Dantrolene Sodium Hemiheptahydrate
Dosage Form & Strength: 120 mg
Route: Intravenous (IV) injection
Drug Class: Skeletal muscle relaxant (ryanodine receptor antagonist)

Manufacturer / Innovator:

Germany

Regulatory Approval:

  • European/UK approved (dantrolene sodium is also marketed in the US as Dantrium/Revonto/Ryanodex)
Family enjoying life with Named Patient Program access

Your Trustedworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant
Licensed Wholesale distributor

What Is Agilus Used For?

Agilus (dantrolene sodium) is a direct-acting skeletal muscle relaxant that blocks calcium release from the sarcoplasmic reticulum. It is indicated for:

  • Treatment of malignant hyperthermia crisis, a rare and life-threatening reaction to certain anesthetic agents
  • Prevention of recurrence following an initial malignant hyperthermia reaction

Agilus is a prescription medicine and must be administered by a physician experienced in managing malignant hyperthermia, in an emergency or perioperative care setting.

Recommended Dosage

  • 2.5 mg/kg by intravenous injection, repeated every 10 minutes as needed until symptoms resolve, up to a cumulative maximum of 10 mg/kg
  • Following successful initial treatment, 1 mg/kg IV every 6 hours for 24 hours to prevent recurrence

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Agilus Warnings and Precautions

  • Hepatotoxicity: Dantrolene has been associated with liver injury; liver function should be monitored, particularly with repeated or prolonged use.
  • Muscle weakness: Agilus can cause significant muscle weakness, which may affect respiratory function; patients should be monitored closely.
  • Extravasation risk: The injection is highly alkaline and can cause tissue damage if it leaks outside the vein; IV access should be secure.
  • Not for chronic spasticity by this route: The intravenous form is intended for acute malignant hyperthermia management, not long-term spasticity treatment.

How to Access Agilus in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Agilus to India?

Agilus (dantrolene sodium) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. Given its use in life-threatening emergencies, hospitals are encouraged to maintain a standing stock through NPP. The following documentation is required:

  • A valid prescription or purchase order from a qualified anesthesiologist or hospital pharmacy
  • Institutional documentation for emergency stock, where applicable
  • Patient or hospital ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription or institutional order and, if applicable, an import permit.

Is Agilus available in India?

Agilus (dantrolene sodium injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Agilus is not commercially marketed in India.

However, hospitals and patients in India can legally access Agilus through the Named Patient Program (NPP) — an import provision that allows access to medicines approved abroad but not yet marketed in India, under proper regulatory documentation.

Agilus is approved in Europe and the UK for the treatment of malignant hyperthermia crisis, ensuring full transparency throughout the process.

Agilus can be made available to hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.

The same active ingredient is also marketed as Dantrium in other markets; NPP can source either brand depending on availability and hospital preference.

Sourcing & Delivery of Agilus

Agilus is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant logistics to preserve product integrity from dispatch to delivery.

  • Storage maintained at 15°C to 30°C throughout transit
  • Real-time shipment tracking and delivery updates
  • Delivery coordinated directly with the treating hospital, including expedited handling for emergency stock requests

Availability of Agilus Across Major Cities in India

Named Patient Program supports hospital access to Agilus for malignant hyperthermia emergency preparedness across major cities in India, coordinating documentation, sourcing, and rapid delivery.

Mumbai

Hospitals in Mumbai can stock Agilus through NPP for anesthesia and critical care emergency readiness.

Delhi

In Delhi, NPP coordinates with hospitals to facilitate timely access to Agilus for surgical and anesthesia departments.

Bangalore

Bangalore's surgical centers work with NPP to maintain Agilus stock for malignant hyperthermia preparedness.

Chennai

Hospitals in Chennai can access Agilus through NPP, with coordination between hospital pharmacy and the program's regulatory and logistics team.

Hyderabad

Hyderabad's surgical and anesthesia centers support access coordination for Agilus through NPP.

Kolkata

NPP facilitates access to Agilus for hospitals in Kolkata for perioperative emergency stock.

Pune

Hospitals in Pune can access Agilus through NPP with prescription-based coordination and delivery support.

Ahmedabad

NPP supports access to Agilus for hospitals in Ahmedabad.

Kochi

Hospitals in Kochi and across Kerala can access Agilus through NPP's regulated import pathway.

Chandigarh

NPP coordinates access to Agilus for hospitals in Chandigarh and the surrounding region.

Jaipur

Hospitals in Jaipur can access Agilus through NPP for surgical emergency preparedness.

Lucknow

NPP facilitates access to Agilus for hospitals in Lucknow and across Uttar Pradesh.

Bhubaneswar

Hospitals in Bhubaneswar can access Agilus through NPP's coordinated import and delivery process.

Guwahati

NPP supports access to Agilus for hospitals in Guwahati and across the Northeast region.

NPP also supports hospitals in other Indian cities not listed above — contact the team to check availability and timelines for your location.

Written By:

Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO

Medically Reviewed By:

Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More